Psoriasis
📧 Sign up to get email alerts when something new happens for Psoriasis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2025-12-01EMA Authorised: Benepali (etanercept) — Samsung Bioepis NL B.V.
The European Medicines Agency authorised Benepali (etanercept), a biosimilar to etanercept, for inflammatory conditions including rheumatoid…
-
EMA approval · 2025-11-21EMA Authorised: Usgena (ustekinumab) — Stada Arzneimittel AG
The European Medicines Agency authorised Usgena, a ustekinumab product from STADA, for treatment of Crohn's disease, psoriasis, psoriatic ar…
-
EMA approval · 2025-11-10EMA Authorised: Flixabi (infliximab) — Samsung Bioepis NL B.V.
The EMA authorised Flixabi, a biosimilar of infliximab, for several inflammatory diseases. The indications include rheumatoid arthritis, pso…
-
EMA approval · 2025-10-22EMA Authorised: Amsparity (adalimumab) — Pfizer Europe MA EEIG
EMA authorised Amsparity (adalimumab) from Pfizer Europe MA EEIG. The biosimilar is approved for multiple autoimmune indications including r…
-
EMA approval · 2025-10-21EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
EMA authorised Idacio, a biosimilar of adalimumab, for multiple inflammatory diseases, produced by Fresenius Kabi Deutschland GmbH. The indi…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-10-08EMA Authorised: Humira (adalimumab) — AbbVie Deutschland GmbH & Co. KG
The EMA authorised Humira (adalimumab) by AbbVie Deutschland GmbH & Co. KG for multiple indications including ankylosing spondylitis, juveni…
-
FDA approval · 2025-10-03FDA Approved: CALCIPOTRIENE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for Calcipotriene from Prasco Laboratories, indicating an addition or modification to the drug's exi…
-
FDA approval · 2025-09-16FDA Approved: FLUOCINOLONE ACETONIDE OIL — Supplemental Application (RISING PHARMA HOLDINGS, INC.)
FDA approved a supplemental application to add Fluocinolone Acetonide Oil as an approved topical formulation of fluocinolone acetonide by Ri…
-
EMA approval · 2025-08-13EMA Authorised: Enbrel (etanercept) — Pfizer Europe MA EEIG
The European Medicines Agency authorised Enbrel (etanercept) for multiple inflammatory diseases including rheumatoid arthritis, ankylosing s…
-
EMA approval · 2025-07-17EMA Authorised: Nordimet (methotrexate) — Nordic Group B.V.
EMA authorised Nordimet (methotrexate) by Nordic Group B.V. for use in arthritis-related conditions including rheumatoid arthritis, psoriati…
-
EMA approval · 2025-07-16EMA Authorised: Ilumetri (tildrakizumab) — Almirall, S.A.
The European Medicines Agency has authorised Ilumetri (tildrakizumab) by Almirall for the treatment of psoriasis.
-
FDA approval · 2025-07-02FDA Approved: ACITRETIN — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
FDA approved a supplemental application for ACITRETIN from Amneal Pharmaceuticals of New York LLC.
-
EMA approval · 2025-06-24EMA Authorised: Zessly (infliximab) — Sandoz GmbH
EMA authorised Zessly (infliximab) from Sandoz GmbH as a biosimilar for treatment of several inflammatory diseases, including rheumatoid art…
-
FDA approval · 2025-04-11FDA Approved: TRIAMCINOLONE ACETONIDE — Original Application (Dr. Reddy's Laboratories Inc)
The FDA approved Dr. Reddy's Laboratories' Triamcinolone Acetonide as an original application (generic) for topical use, adding a generic co…
-
EMA approval · 2025-03-17EMA Authorised: Skilarence (dimethyl fumarate) — Almirall, S.A.
EMA has authorized Skilarence (dimethyl fumarate) for the treatment of psoriasis, with Almirall, S.A. as the marketing authorization holder.
-
EMA approval · 2025-03-03EMA Authorised: Nepexto (etanercept) — Biosimilar Collaborations Ireland Limited
EMA authorised Nepexto, a biosimilar of etanercept, developed by Biosimilar Collaborations Ireland Limited, for several inflammatory arthrit…
-
FDA approval · 2025-02-26FDA Approved: FLUOCINONIDE — Original Application (QUAGEN PHARMACEUTICALS LLC)
FDA approved fluocinonide from Quagen Pharmaceuticals LLC under an Original Application (ANDA 216389). This is a generic topical corticoster…
-
FDA approval · 2024-12-09FDA Approved: TRIAMCINOLONE ACETONIDE — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approval of Hikma's generic Triamcinolone Acetonide (ANDA 215254) as an original-application topical corticosteroid product for dermatol…
-
EMA approval · 2024-10-24EMA Authorised: Jylamvo (methotrexate) — Oresund Pharma ApS
The European Medicines Agency authorised Jylamvo, a methotrexate product from Oresund Pharma ApS, for indications including psoriatic arthri…
-
FDA approval · 2024-10-23FDA Approved: JYLAMVO — Supplemental Application (SHORLA ONCOLOGY INC.)
The FDA approved a supplemental application for JYLAMVO (methotrexate) filed by SHORLA ONCOLOGY INC.
-
FDA approval · 2024-08-22FDA Approved: BETAMETHASONE VALERATE — Original Application (Alembic Pharmaceuticals Limited)
FDA approved an original ANDA for Betamethasone Valerate topical (Alembic Pharmaceuticals), a generic corticosteroid product for inflammator…
-
FDA approval · 2024-08-05FDA Approved: ACITRETIN — Original Application (Alembic Pharmaceuticals Inc.)
FDA approved the Original Application for Acitretin from Alembic Pharmaceuticals Inc., a generic version of this retinoid. Acitretin is used…
-
FDA approval · 2024-07-15FDA Approved: TAZAROTENE — Original Application (Padagis Israel Pharmaceuticals Ltd)
FDA approved Padagis Israel Pharmaceuticals Ltd's Original Application for Tazarotene, establishing a generic topical retinoid. The product …
-
EMA approval · 2024-07-04EMA Authorised: Sotyktu (deucravacitinib) — Bristol-Myers Squibb Pharma EEIG
The European Medicines Agency authorised Sotyktu (deucravacitinib) by Bristol-Myers Squibb Pharma EEIG for psoriasis in the European Union.
-
FDA approval · 2024-06-03FDA Approved: METHOTREXATE — Original Application (Alembic Pharmaceuticals Inc.)
FDA approved Alembic Pharmaceuticals' original application for methotrexate, authorizing the generic version of the drug.